Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Mometasone Furoate is a potent medium-strength corticosteroid used to treat inflammatory conditions such as asthma, allergic rhinitis, and various dermatological disorders by reducing swelling and immune responses.
Name
Mometasone Furoate
Raw Name
MOMETASONE FUROATE
Category
Other
Drug Count
18
Variant Count
57
Last Verified
February 17, 2026
RxCUI
746803, 746804, 746810, 746811, 746812, 746813, 746814, 746815, 790283, 790284, 151029, 1797865, 151030, 311753, 1797870, 2591806, 2591812, 1536142, 1536144, 1536147, 1536148, 2196790, 2196792, 1246308, 1246310, 1246311, 1246313, 1660933, 1660934, 1660937, 1660938, 2196590, 2196592, 1995983, 1995988
UNII
04201GDN4R, MTW0WEG809, 2XG66W44KF, W34SHF8J2K
About Mometasone Furoate
Mometasone Furoate is a potent medium-strength corticosteroid used to treat inflammatory conditions such as asthma, allergic rhinitis, and various dermatological disorders by reducing swelling and immune responses.
Detailed information about Mometasone Furoate
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Mometasone Furoate.
Mometasone Furoate is a highly potent, synthetic 17-heterocyclic corticosteroid (glucocorticoid) with significant anti-inflammatory, antipruritic (anti-itching), and vasoconstrictive (blood vessel narrowing) properties. It belongs to a class of medications known as topical or inhaled corticosteroids, depending on the route of administration. Since its initial FDA approval in 1987 for topical use, followed by nasal approval in 1997 and inhalation approval in 2004, Mometasone Furoate has become a cornerstone in the management of chronic inflammatory conditions. Unlike older corticosteroids, Mometasone Furoate is characterized by its high lipophilicity (ability to dissolve in fats) and high affinity for the glucocorticoid receptor, which allows for localized action with minimal systemic (body-wide) absorption. This pharmacological profile makes it exceptionally useful for treating localized inflammation in the respiratory tract and the skin while reducing the risk of systemic side effects typically associated with oral steroids.
At the molecular level, Mometasone Furoate functions by diffusing across cell membranes and binding with high affinity to cytoplasmic glucocorticoid receptors (GR). Once bound, the drug-receptor complex undergoes a conformational change and translocates into the cell nucleus. Within the nucleus, the complex binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs). This interaction leads to two primary mechanisms of action: transactivation and transrepression.
In transactivation, the drug increases the expression of anti-inflammatory proteins, such as lipocortin-1 (annexin-1), which inhibits the enzyme phospholipase A2. By inhibiting this enzyme, Mometasone Furoate effectively blocks the 'arachidonic acid cascade,' preventing the production of potent inflammatory mediators like prostaglandins and leukotrienes. In transrepression, the drug-receptor complex interferes with the activity of pro-inflammatory transcription factors, such as Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1). This action suppresses the synthesis of various cytokines (IL-1, IL-4, IL-5, IL-13), chemokines, and adhesion molecules that are responsible for the recruitment and activation of inflammatory cells like eosinophils, mast cells, and T-lymphocytes. The result is a profound reduction in tissue edema (swelling), mucus secretion, and airway hyperresponsiveness in asthma or skin redness and thickening in dermatitis.
Understanding the pharmacokinetics of Mometasone Furoate is essential for clinical practice, as the drug is designed to act locally with negligible systemic presence.
Mometasone Furoate is FDA-approved for several distinct clinical indications across different delivery systems:
Mometasone Furoate is available in several formulations to target specific areas of inflammation:
> Important: Only your healthcare provider can determine if Mometasone Furoate is right for your specific condition. Proper diagnosis and selection of the appropriate delivery method are crucial for effective treatment.
Dosage for Mometasone Furoate varies significantly based on the condition being treated and the delivery system used.
No dosage adjustment is typically required for patients with renal impairment, as systemic absorption is extremely low and renal clearance is not the primary route of elimination for the parent drug.
While Mometasone Furoate is metabolized by the liver, the very low systemic levels usually mean that dose adjustments are not necessary for mild to moderate hepatic impairment. However, patients with severe hepatic disease should be monitored for signs of systemic corticosteroid effects (e.g., Cushingoid features) due to potentially reduced clearance of the small amount of absorbed drug.
Clinical studies have not identified significant differences in safety or efficacy between elderly patients and younger adults. However, as with all corticosteroids, the lowest effective dose should be used to minimize the risk of age-related complications like skin thinning or bone density loss.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up.
Acute overdose is unlikely to be life-threatening due to low systemic bioavailability. However, chronic overexposure (using too much for too long) can lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome (weight gain in the upper body, moon face), and growth retardation in children. If significant overdose is suspected, contact a poison control center or seek emergency medical care.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication abruptly without medical guidance.
Side effects vary by the route of administration. For the nasal spray, the most common side effects include:
For the inhaler (Asmanex), common effects include:
> Warning: Stop taking Mometasone Furoate and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of Mometasone Furoate, especially at high doses, may lead to:
There are currently no FDA Black Box Warnings for Mometasone Furoate. However, the FDA requires prominent warnings regarding the risk of transferring from systemic (oral) corticosteroids to localized (inhaled/nasal) forms, as this can lead to adrenal crisis.
Report any unusual symptoms to your healthcare provider to ensure your treatment remains safe and effective.
Mometasone Furoate is a potent medication that must be used with caution. It is not a "rescue" medication and will not stop an acute asthma attack or a sudden allergic reaction. Patients must be aware that the benefits of Mometasone Furoate are cumulative; it may take several days or even weeks of consistent use to achieve maximum therapeutic effect. It is vital to use the medication exactly as prescribed, even when symptoms are not present.
No FDA black box warnings for Mometasone Furoate. However, clinicians emphasize the "Warning" section regarding the transition from oral steroids, which can be life-threatening if not managed by a slow taper.
Healthcare providers typically monitor the following during long-term Mometasone Furoate therapy:
Mometasone Furoate generally does not interfere with the ability to drive or operate machinery. It does not cause sedation.
There is no direct contraindication between Mometasone Furoate and moderate alcohol consumption. However, alcohol can sometimes worsen nasal congestion or asthma symptoms in sensitive individuals.
Do not stop using Mometasone Furoate suddenly, especially if you have been using it for asthma or in high doses. Sudden discontinuation can lead to a return of symptoms or, in rare cases, withdrawal symptoms like joint pain, weakness, and depression. Your doctor will provide a tapering schedule if the medication needs to be stopped.
> Important: Discuss all your medical conditions, especially any history of tuberculosis, herpes simplex of the eye, or recent infections, with your healthcare provider before starting Mometasone Furoate.
While there are no absolute drug-drug contraindications that apply to everyone, Mometasone Furoate should not be used with other potent corticosteroids unless directed by a specialist, as this significantly increases the risk of systemic toxicity and HPA axis suppression.
For each major interaction, the primary management strategy is dose minimization and vigilant clinical monitoring for signs of steroid excess (weight gain, skin thinning, high blood sugar).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those bought over-the-counter.
Mometasone Furoate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis before use include:
Patients who have had severe allergic reactions to other corticosteroids (such as fluticasone, budesonide, or triamcinolone) may be at an increased risk of a reaction to Mometasone Furoate. While cross-reactivity is not guaranteed, it should be discussed with an allergist or healthcare provider.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of infections or previous steroid reactions, before prescribing Mometasone Furoate.
Mometasone Furoate is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that systemic exposure to corticosteroids can cause fetal malformations (like cleft palate), but the systemic exposure from nasal or inhaled mometasone at clinical doses is extremely low. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be observed for signs of hypoadrenalism.
It is not known whether Mometasone Furoate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug. However, given the very low systemic bioavailability of mometasone, the amount reaching the milk is expected to be negligible.
Warning: Corticosteroids may cause a reduction in growth velocity in children. Pediatric patients should receive the lowest dose possible to maintain control of symptoms, and their growth (height) should be monitored regularly. Safety and efficacy in children under 2 years for rhinitis or 4 years for asthma have not been established.
Clinical trials included a sufficient number of patients aged 65 and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. However, elderly patients may be more prone to skin thinning (with topical use) or have a higher baseline risk for cataracts and glaucoma, requiring more frequent monitoring.
No dose adjustment is required for patients with renal impairment. The drug is primarily excreted via the feces, and systemic levels are too low for renal function to significantly impact the drug's safety profile.
Since Mometasone Furoate is metabolized by CYP3A4 in the liver, severe hepatic impairment could theoretically lead to increased systemic levels. While no specific dose adjustments are provided by the manufacturer, these patients should be monitored for signs of systemic corticosteroid excess (e.g., increased blood pressure, weight gain).
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Mometasone Furoate is a medium-potency corticosteroid that acts as a potent agonist at the glucocorticoid receptor. Its primary mechanism involves the inhibition of multiple inflammatory cell types (mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and the release of mediators (histamine, eicosanoids, leukotrienes, and cytokines). By binding to the glucocorticoid receptor, it alters gene expression, leading to a decrease in the production of pro-inflammatory proteins and an increase in anti-inflammatory proteins. This results in reduced capillary permeability and a decrease in the swelling and irritation of the affected tissues.
The pharmacodynamics of Mometasone Furoate are characterized by a high local anti-inflammatory effect with minimal systemic activity. In the nose, it reduces the nasal 'early-phase' and 'late-phase' allergic reactions. In the lungs, it reduces airway inflammation and hyperresponsiveness. The onset of action for the nasal spray is typically within 11 to 48 hours, with maximum benefit often reached after 1 to 2 weeks of consistent use.
| Parameter | Value |
|---|---|
| Bioavailability | <1% (Nasal/Inhalation) |
| Protein Binding | 98% to 99% |
| Half-life | 5.8 hours (Nasal); 58 hours (Inhaled) |
| Tmax | ~1-2.5 hours (post-inhalation) |
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Fecal (primarily), Renal (<5%) |
Mometasone Furoate is classified as a synthetic glucocorticoid corticosteroid. In the context of respiratory medicine, it is an Intranasal Corticosteroid (INS) or an Inhaled Corticosteroid (ICS). In dermatology, it is a medium-potency topical corticosteroid (Group II or III depending on the specific formulation).
Medications containing this ingredient
Common questions about Mometasone Furoate
Mometasone Furoate is a versatile corticosteroid used to treat several inflammatory conditions depending on its formulation. As a nasal spray, it is commonly prescribed for seasonal and perennial allergic rhinitis (hay fever) and nasal polyps in adults. In its inhaled form, it is used as a long-term maintenance treatment for asthma to prevent symptoms like wheezing and shortness of breath. The topical cream or ointment is used to treat skin conditions such as psoriasis and eczema by reducing redness, itching, and swelling. It works by suppressing the immune system's inflammatory response at the site of application.
The side effects of Mometasone Furoate depend on how it is administered. For the nasal spray, patients frequently report headaches, minor nosebleeds (epistaxis), and sore throats. When used as an inhaler for asthma, common side effects include oral thrush (a fungal infection in the mouth), hoarseness, and upper respiratory tract infections. Topical use on the skin may cause burning, itching, or thinning of the skin if used for long periods. Most side effects are localized to the area where the medication is applied and are generally mild.
There is no known direct interaction between alcohol and Mometasone Furoate. Because the medication is mostly absorbed locally in the nose, lungs, or skin, very little enters the bloodstream to interact with alcohol. However, alcohol can sometimes trigger or worsen asthma symptoms or nasal congestion in certain individuals. It is always best to observe how your body reacts to the medication before consuming alcohol. If you have concerns, consult your healthcare provider regarding your specific health status.
Mometasone Furoate is generally considered to have a low risk during pregnancy because very little of the drug reaches the systemic circulation. However, it is officially classified as Pregnancy Category C, meaning there are no definitive human studies to prove its safety. Doctors usually prescribe it only if the benefits to the mother outweigh the potential risks to the developing fetus. Animal studies have shown some risks at very high doses, but these are much higher than what a human would typically use. Always consult your obstetrician before using any steroid medication while pregnant.
Mometasone Furoate does not provide immediate relief like a decongestant or a rescue inhaler. For allergic rhinitis, some patients may notice an improvement within 11 to 12 hours, but it usually takes about 1 to 2 weeks of daily use to feel the full therapeutic effect. For asthma, it may take 1 to 2 weeks or longer for your breathing to improve significantly. Consistency is key with this medication; it must be used every day as prescribed to keep inflammation under control, even if you are feeling well.
You should not stop taking Mometasone Furoate suddenly, especially if you are using the inhaled version for asthma. Stopping abruptly can cause your asthma symptoms to return quickly and severely. If you have been using high doses or have recently switched from oral steroids, stopping suddenly could also lead to symptoms of withdrawal or adrenal insufficiency. Always talk to your doctor before discontinuing the medication. They will likely provide a schedule to gradually reduce your dose to ensure your condition remains stable.
If you miss a dose of Mometasone Furoate, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular timing. Do not take two doses at once to make up for the one you missed. To get the best results, try to take your medication at the same time every day to maintain a consistent level of the drug in your system. Setting a daily reminder on your phone can help you stay on track.
Weight gain is a common side effect of oral corticosteroids (like prednisone), but it is very rare with Mometasone Furoate. Because mometasone is applied locally (to the nose, lungs, or skin) and has very low systemic absorption, it does not typically cause the metabolic changes that lead to weight gain. If you experience significant or rapid weight gain while using this medication, it may be a sign of excessive systemic absorption or another underlying medical issue. You should discuss any unusual weight changes with your healthcare provider immediately.
Mometasone Furoate can be taken with most other medications, but there are some important exceptions. You should be cautious if you are taking strong CYP3A4 inhibitors, such as certain HIV medications (ritonavir) or antifungal drugs (ketoconazole), as these can increase the amount of mometasone in your blood. It is also important to tell your doctor if you are using other steroid medications, such as prednisone or steroid creams, to avoid a 'steroid overdose.' Always provide your healthcare provider with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use.
Yes, Mometasone Furoate is available as a generic medication in several forms, including the nasal spray, topical cream, and ointment. Generic versions are typically more cost-effective than brand-name products like Nasonex or Elocon and are required by the FDA to have the same active ingredient, strength, and effectiveness. Some inhalation forms, like the Asmanex Twisthaler, may also have generic alternatives available depending on your region and insurance coverage. Check with your pharmacist to see if a generic version is appropriate for your specific prescription.